Lexaria (CSE: LXX) announces significant findings on CBD

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced additional significant findings upon completion of further data analyses from its 2018 randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD™. The initial results from this study were published on August 1, 2018 and showed that the LXRP technology improved the delivery of CBD from a proprietary DehydraTECHTM powered, cannabidiol (CBD) fortified hemp oil capsule across 30, 60 and 90 minute time periods as well as through to the 6-hour mark when the study was completed.

Additional new findings from this study showed a single 90 mg dose of TurboCBD provided evidence of lower blood pressure; higher blood flow to the brain; faster delivery onset of CBD into the bloodstream; and, larger quantities of CBD within the blood compared to a single 90mg dose of generic CBD. More specifically:

• Analysis of mean arterial blood pressure (MAP) at peak blood levels of CBD demonstrated a significant reduction in MAP compared to a placebo;

• Cerebral perfusion was also analysed by an index of conductance in the middle cerebral artery (MCA) and revealed Lexaria’s TurboCBD™ caused the greatest increase in MCA conductance relative to both the positive control formulation and a placebo;

• Over the six-hour study, analysis of the total area under the curve (AUC) demonstrated that TurboCBD™ resulted in a notable trend for higher levels of CBD in the bloodstream overall.

One thing I have always appreciated about LXRP’s management is their commitment to scientific research and building a portfolio of intellectual property. Each study produces additional information regarding the validity of DehydraTECHTM and adds to my confidence level. The investment conclusion is simple. If Altria (NYSE: MO) spends its $12 million researching LXRP’s technology, I believe they will find what they are looking for and if they do, they will be motivated to buy Lexaria Nicotine or could opt to pay a royalty for the use of the technology. If that happens, it will represent another major step toward unlocking some of Lexaria’s potential shareholder value.